Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 1:59 AM
Study NCT ID:
NCT05303805
Status:
RECRUITING
Last Update Posted:
2024-08-27
First Post:
2022-02-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Topical Sevoflurane for Treatment of Chronic Leg Ulcers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007871', 'term': 'Leg Ulcer'}, {'id': 'D010146', 'term': 'Pain'}, {'id': 'D003141', 'term': 'Communicable Diseases'}], 'ancestors': [{'id': 'D012883', 'term': 'Skin Ulcer'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077149', 'term': 'Sevoflurane'}], 'ancestors': [{'id': 'D008738', 'term': 'Methyl Ethers'}, {'id': 'D004987', 'term': 'Ethers'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D006845', 'term': 'Hydrocarbons, Fluorinated'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT'], 'maskingDescription': 'Patient will separated by a screen from the treated area. Absorbent material with sevoflurane will be held under the distal pole of the wound to produce a typical smell of sevoflurane.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The intervention group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with , with sevoflurane used to soak the absorbent material held under the distal pole of the wound to produce a typical smell of sevoflurane.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 50}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-05-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-08', 'completionDateStruct': {'date': '2027-01-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-08-24', 'studyFirstSubmitDate': '2022-02-27', 'studyFirstSubmitQcDate': '2022-03-21', 'lastUpdatePostDateStruct': {'date': '2024-08-27', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-03-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-04-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain intensity', 'timeFrame': 'Continuously for 5 days', 'description': 'Pain intensity measured by numeric rating scale (NRS) from 0 - no pain (the best result) to 10 - the worst possible pain using a standard questionnaire'}], 'secondaryOutcomes': [{'measure': 'Microbial colonization', 'timeFrame': 'Before application of treatment, after the 1st application before tibial coverage and on the 5th day after application', 'description': 'Microbial smear for culture'}, {'measure': 'Size of skin defect', 'timeFrame': '5 days', 'description': 'Measured in cm2'}, {'measure': 'Appearance of the ulcer bed', 'timeFrame': '5 days', 'description': 'Epithelial tissue, granulation tissue, slough, necrotic tissue'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Leg Ulcer', 'Sevoflurane', 'Pain', 'Healing ulcer', 'Microbial colonization'], 'conditions': ['Leg Ulcer']}, 'descriptionModule': {'briefSummary': 'Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early.\n\nExclusion criteria: allergy to sevoflurane, inability to understand the questionnaire\n\nParameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect', 'detailedDescription': 'A prospective single-blinded randomized study will be conducted in patients of the Dermatovenereology Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the University Hospital Kralovske Vinohrady (FNKV) with painful non-healing tibial ulcers. Pain intensity on a numerical rating scale (NRS 0-10) must be NRS\\>4. The envelope method will be used for randomization. To blind patients, therapy will be performed by separating patients with a drape from the treatment area of the body. As sevoflurane has a typical odor, it will only be used in the control group to soak up absorbent material held under the distal pole of the wound without skin contact. In the active treatment group, sevoflurane will be applied at the beginning of the wound treatment at approximately 1 ml/cm2 of the ulcer surface. The standard therapy used in the control group will use only Cyteal TM lavage solution, which contains hexamidine diisetione 100 mg in 100 ml, chlorhexidine digluconate 20% solution 100 mg and chlorocresol 300 mg.\n\nThe primary aim of the study will be pain relief after sevoflurane therapy. Pain intensity will be measured by NRS at 1-hour intervals (excluding sleep); decrease of 2 point for at least 4 hours will be considered significant. Secondary aim will be healing of ulcers. The effect will be controlled by elimination of pathologic microbial colonization, cleaning of the base of the wound and decreasing the size of the ulcer. Microbial colonization will be measured by microbial swab culture before application, after the 1st application before dressing and on the 5th day after application), the appearance of the defect base will be assessed by the appearance of the surface, the size of the defect will be measured in cm2.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with painful (pain intensity on the numerical scale NRS 0-10 is NRS\\>4) non- healing tibial venous ulcers\n\nExclusion Criteria:\n\n* Allergy to sevoflurane\n* Inability to understand the pain-intensity questionnaire'}, 'identificationModule': {'nctId': 'NCT05303805', 'briefTitle': 'Topical Sevoflurane for Treatment of Chronic Leg Ulcers', 'organization': {'class': 'OTHER', 'fullName': 'Charles University, Czech Republic'}, 'officialTitle': 'Analgesic and Healing Effect of Topical Sevoflurane for Chronic Venous Ulcers', 'orgStudyIdInfo': {'id': 'Sevoflurane in ulcers'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Topical sevoflurane', 'description': 'The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment,', 'interventionNames': ['Drug: Sevoflurane']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Cyteal', 'description': 'the control group will only have a standard rinse solution with Cyteal PIERRE FABRE MEDICAMENT, France (100 ml of skin fluid contains hexamidine diisetione 100 mg, chlorohexidine digluconate (solutio 20 %) 100 mg and chlorocresol 300 mg), with sevoflurane used to soak the absorbent material held under the distal pole of the wound.', 'interventionNames': ['Combination Product: Cyteal']}], 'interventions': [{'name': 'Sevoflurane', 'type': 'DRUG', 'otherNames': ['Sevorane'], 'description': 'Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.', 'armGroupLabels': ['Topical sevoflurane']}, {'name': 'Cyteal', 'type': 'COMBINATION_PRODUCT', 'description': 'Rinsing and cleaning of ulcer.', 'armGroupLabels': ['Cyteal']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100 00', 'city': 'Prague', 'status': 'RECRUITING', 'country': 'Czechia', 'contacts': [{'name': 'Jiri Malek, M.D.', 'role': 'CONTACT'}, {'name': 'Spyridon Gkalpakiotis, M.D.', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Alice Kurzova, M.D.', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Faculty Hospital Kralovske Vinohrady', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}], 'centralContacts': [{'name': 'Jiri Malek, M.D.', 'role': 'CONTACT', 'email': 'malekj@fnkv.cz', 'phone': '+4202671622461'}, {'name': 'Jiri Malek, M.D.', 'role': 'CONTACT', 'email': 'malekj@fnkv.cz', 'phone': '+4202671622272461'}], 'overallOfficials': [{'name': 'Jiří Málek, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': '3rd Medical Faculty of Charles University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Charles University, Czech Republic', 'class': 'OTHER'}, 'collaborators': [{'name': 'Faculty Hospital Kralovske Vinohrady', 'class': 'OTHER_GOV'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Assoc. Prof. Jiri Malek, MD, Ph.D.', 'investigatorFullName': 'Jiri Malek', 'investigatorAffiliation': 'Charles University, Czech Republic'}}}}